polatuzumab vedotin,vincristine
roche
['polatuzumab', 'pola', 'dlbcl', ' vedo', 'vincristine']
polatuzumab vedotin in place of vincristine in r-mini-chop did not increase high-grade hematologic toxicities, infection risk, or neuropathy in elderly patients with untreated #dlbcl. #eha2023 
Oncology news and insights from leading researchers and cancer centers.